Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Int J Nanomedicine. 2020 Jun 9;15:4001-4020. doi: 10.2147/IJN.S256925. eCollection 2020.
Simvastatin (SMV), a hypocholesterolemic agent, suffers from very low bioavailability due to its poor aqueous solubility and extensive first-pass metabolism.
Two SMV carrier systems, namely, polymeric drug inclusion complex (IC) and mixed micelles (MM) nanoparticles, were developed and loaded into mucoadhesive buccal films to enhance SMV bioavailability. The two carrier systems were characterized and their permeation across human oral epithelial cells (OEC) was studied. The effect of IC to MM ratio (X) and the mucoadhesive polymer concentration (X) on the cumulative percent of drug released, elongation percent and the mucoadhesive strength, from the prepared mucoadhesive films, were optimized. Ex vivo permeation across bovine mucosal tissue was investigated. The permeation parameters for the in vitro and ex vivo release data were calculated.
Complexation of SMV with hydroxypropyl beta-cyclodextrin (HP β-CD) was superior to all other polymers as revealed by the equilibrium saturation solubility, stability constant, complexation efficiency and thermodynamic potential. SMV-HP β-CD IC was utilized to develop a saturated polymeric drug solution. Both carrier systems showed enhanced permeation across OEC when compared to pure drug. X and X were significantly affecting the characteristics of the prepared films. The optimized mucoadhesive buccal film formulation loaded with SMV IC and drug MM nanoparticles demonstrated superior ex vivo permeation when compared to the corresponding pure drug buccal film, and the calculated permeation parameters confirmed this finding.
Mucoadhesive buccal films containing SMV IC and drug MM can be used to improve drug bioavailability; however, additional pharmacokinetic and pharmacodynamic studies are required.
辛伐他汀(SMV)是一种降胆固醇药物,由于其水溶性差和广泛的首过代谢,生物利用度非常低。
开发了两种 SMV 载体系统,即聚合物药物包合物(IC)和混合胶束(MM)纳米粒子,并将其载入粘膜粘附颊膜中,以提高 SMV 的生物利用度。对两种载体系统进行了表征,并研究了它们在人口腔上皮细胞(OEC)中的渗透。优化了 IC 与 MM 比(X)和粘膜粘附聚合物浓度(X)对从制备的粘膜粘附膜中释放的累积药物百分比、伸长百分比和粘膜粘附强度的影响。研究了体外透过牛粘膜组织的情况。计算了体外和体内释放数据的渗透参数。
SMV 与羟丙基-β-环糊精(HPβ-CD)的络合作用优于所有其他聚合物,这表现在平衡饱和溶解度、稳定常数、络合效率和热力学潜力上。SMV-HPβ-CD IC 用于开发饱和聚合物溶液。与纯药物相比,两种载体系统均显示出对 OEC 的渗透增强。X 和 X 对制备的薄膜的特性有显著影响。载有 SMV IC 和药物 MM 纳米粒子的优化粘膜粘附颊膜制剂与相应的纯药物颊膜制剂相比,表现出优越的体外渗透,计算出的渗透参数证实了这一发现。
含有 SMV IC 和药物 MM 的粘膜粘附颊膜可用于提高药物生物利用度;然而,需要进行额外的药代动力学和药效学研究。